The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as increased application of immunoglobulins for treatment of various therapeutic areas such as hematology, neurology and pulmonology, and the use of protease inhibitors for the treatment of lung diseases and hepatic diseases that have growing incidence rate. However, the increased cost of plasma products, limited reimbursements, and the growth of recombinant alternatives are expected to restrain the growth of this market during the forecast period.
The global plasma fractionation market is highly consolidated. The prominent players operating in this market include CSL (Australia), Grifols, S.A. (Spain), Shire (US), Octapharma AG (Switzerland), Kedrion S.P.A (Italy), LFB (France), Biotest AG (Germany), Sanquin (Netherlands), China Biologic Products Holdings Inc. (China), GC Pharma (Korea), Bio Products Ltd. (UK), Japan Blood Products Organization (Japan), Emergent BioSolutions (US), Shanghai Raas Blood Products Co., Ltd. (China), Intas Pharmaceuticals Ltd. (India), Bharat Serum Vaccines Limited (India), SK Plasma (Korea), Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China), KabaFusion (US), Centurion Pharma (Istanbul), ADMA Biologics, Inc. (US), PlasmaGen BioSciences Pvt. Ltd. (India), Virchow Biotech Private Limited (India), Fusion Healthcare (India), and Hemarus Therapeutics Limited (India). Geographic expansions and collaborations are the key growth strategies undertaken by these companies to maintain their positions in the market.
To know about the assumptions considered for the study download the pdf brochure
In 2021, CSL dominated the plasma fractionation market with a share of 30–35%. It also established itself as a global leader in this market, by focusing on strengthening its presence in the emerging markets. In 2017, CSL invested USD 174 million for capacity expansion to increase its production capacity of albumin at its Broadmeadows facility (Melbourne, Australia) and In 2019, the company announced an investment of USD 203 million at Marburg, Germany, to cater to the increased demand for plasma fractionation products. Such investment in opening new centers and existing presence in 35 countries with over 230 plasma collection centers, in North America, Europe, Australia, and Asia Pacific ensure that their products are available globally.
Continuous investments in R&D have also enabled the company to emerge as a leading provider of plasma fractionation products. In the last five years, the company invested around USD 3.3 billion in developing and delivering innovative biotherapies; it has more than 1,700 employees dedicated to R&D activities.
However, the company’s involvement in legal proceedings and the decline in liquidity ratio could hamper its growth to a certain extent. Stringent government regulations and unfavorable currency exchange rates may also affect the company’s growth in the coming years.
Grifols accounted for a share of 15–20% of the plasma fractionation market in 2021. Grifols is a global healthcare company specializing in developing, manufacturing, and distributing plasma-derived products. The company focuses on research and product innovation to maintain its leading position in the market. Grifols invests heavily in R&D, as well as partners with research institutes to develop advanced plasma-derived products to fight rare diseases. The company also constantly focuses on expanding its plasma collection centers and increasing its capacity. It has more than 190 centers in the US and 35 in Europe.
Shire accounted for a share of 11–16% of the plasma fractionation market in 2021. In 2019, Shire was acquired by Takeda. Since Takeda is an internationally recognized brand, the acquisition will help Shire gain a competitive edge in the market. The company’s leading position in the market can also be attributed to its expertise in medical devices, pharmaceuticals, and biotechnology. BioLife, a part of Takeda, is a global plasma collection network that collects high-quality plasma.
Shire also has more than 80 plasma collection facilities in 24 states of the US and at 7 locations in Austria, which helps increase its productivity without making it necessary for the company to spend on outsourcing plasma. The company also maintains relationships with other plasma suppliers to meet the market demand for its plasma-based therapies.
Octapharma AG accounted for 8–12% of the plasma fractionation market in 2021. Octapharma invests in research to advance its existing products as well as investigate new therapeutic uses of human protein products derived from human blood plasma and human cell lines. The company focuses on organic and inorganic growth strategies such as collaborations, product launches, and expansions.
The company also focuses on adopting various promotional strategies to increase brand awareness in the plasma fractionation market. Since 2018, the company has received seven approvals from various regulatory bodies.
Kedrion accounted for 2–5% of the plasma fractionation market in 2021. The company has a robust presence in about 100 countries across Asia, Europe, North America, and South America, and 24 plasma collection centers worldwide. Kedrion strategically focuses on collaborations and agreements as its key growth strategy. The company also collaborates with various hemophilia institutes to provide sustainable access to hemophilia treatment by donating plasma-derived products to various developing as well as European countries that do not meet the minimum standards of hemophilia care.
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) - Global Forecast to 2027
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE